Create a free research account to view current pricing and place an order.
Mechanism of action
BPC-157 is researched for tissue-repair signaling involving angiogenesis, nitric-oxide pathways, inflammatory modulation, fibroblast activity, tendon/ligament remodeling, and gastrointestinal mucosal-support mechanisms. Human pharmacokinetic and clinical standardization remain limited. TB-500 is a thymosin beta-4 fragment researched for actin-binding biology, cell migration, angiogenesis, tissue remodeling, and soft-tissue repair signaling. It is often paired conceptually with BPC-157 in regenerative protocols.
Half-life & pharmacokinetics
Half-life: Blend; component PK differs.
Blend pharmacokinetics vary by component. Operational timing should be based on the dominant pathway and the most sensitivity-prone ingredient.
Research dosing reference
1-2 mg total blend daily or protocol-specific repair exposure.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 5/5 mg | 2 mL BAC Water | 0.050 mg/unit |
| 10/10 mg | 2 mL BAC Water | 0.100 mg/unit |
Injection timing
Daily or split AM/PM depending on protocol objective. Local versus systemic placement should be determined by research design and clinician preference.
Beginner escalation
Start with conservative exposure to evaluate injection-site tolerance and systemic response before increasing or layering additional repair agents.
Side-effect mitigation
Monitor injection irritation, transient fatigue, headache, flushing, or unexpected inflammatory response. Rotate sites and preserve sterile technique.
Stack compatibility
Commonly paired with complementary repair pathways such as BPC-157, TB-500, GHK-Cu, KPV, or SS-31 depending on tissue target.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Acute repair protocols are commonly structured as 2-6 week focused blocks, then reassess pain, mobility, inflammatory response, and tissue objective. Maintenance, if used, should be lower-frequency and objective-driven.
Frequently asked questions
What is BPC-157/TB500 and how does it work?
BPC-157 is researched for tissue-repair signaling involving angiogenesis, nitric-oxide pathways, inflammatory modulation, fibroblast activity, tendon/ligament remodeling, and gastrointestinal mucosal-support mechanisms. Human pharmacokinetic and clinical standardization remain limited. TB-500 is a thymosin beta-4 fragm
What is the half-life of BPC-157/TB500?
BPC-157/TB500: Blend; component PK differs. Blend pharmacokinetics vary by component. Operational timing should be based on the dominant pathway and the most sensitivity-prone ingredient.
How is BPC-157/TB500 reconstituted for research?
Preferred reconstitution for the 5/5 mg vial is 2 mL BAC Water, giving 0.050 mg/unit. Always confirm concentration math before any use. Research use only.
Is BPC-157/TB500 FDA approved?
No. BPC-157/TB500 is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration